Wednesday August 23rd 2017

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec and Sangamo BioSciences, Inc. announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin.

From: 

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Leave a Comment

More from category

Novartis launches MS study using data collected from smartphones
Novartis launches MS study using data collected from smartphones

Novartis (NYSE:NVS) said today that it is launching a research study to better understand the daily challenges facing [Read More]

McDonald criteria: MS diagnosis guidelines
McDonald criteria: MS diagnosis guidelines

Learn about the McDonald criteria. What is dissemination in space, what is dissemination in time, and what additional [Read More]

Multiple sclerosis: Are we close to a cure?
Multiple sclerosis: Are we close to a cure?

Read this article: Multiple sclerosis: Are we close to a cure? [Read More]

Medical News Today: McDonald criteria: MS diagnosis guidelines
Medical News Today: McDonald criteria: MS diagnosis guidelines

Learn about the McDonald criteria. What is dissemination in space, what is dissemination in time, and what additional [Read More]

Medical News Today: Multiple sclerosis: Are we close to a cure?
Medical News Today: Multiple sclerosis: Are we close to a cure?

Discoveries and breakthroughs in multiple sclerosis research are building momentum, but just how close are we to [Read More]